NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-158-2007-3-US-07 LIVE ATTENUATED VIRUS VACCINES FOR LA CROSSE VIRUS AND OTHER BUNYAVIRIDAE US CON 16/750,437 Abandoned
NIAMS E-192-2017-0-EP-04 ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF HEPATITIS B VIRUS INFECTION EP National Stage 18750051.7 Issued
NIAID E-103-2014-3-AU-13 Antibody Evolution Immunogens AU DIV 2020200453 Abandoned
NCI E-029-2019-0-TW-02 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION TW ORD 109102511 Pending
Leidos E-039-2017-0-US-04 Phenyl Indole Allosteric Inhibitors Of P97 ATPase US DIV 16/748,654 11247985 Issued PDF
NCI E-029-2019-0-PCT-03 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12R MUTATION PCT PCT PCT/US2020/014382 Expired
NCI E-750-2013-0-US-19 METHOD FOR SUBTYPING LYMPHOMA TYPES BY MEANS OF EXPRESSION PROFILING US CON 16/746,347 11574704 Issued PDF
NIAMS E-192-2017-0-IL-05 ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF HEPATITIS B VIRUS INFECTION IL National Stage 272094 Issued
NIAMS E-192-2017-0-US-06 ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF HEPATITIS B VIRUS INFECTION US National Stage 16/631,290 11827669 Issued PDF
NCI E-028-2019-0-PCT-02 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-1 AND METHODS OF USE PCT PCT PCT/US2020/013739 Expired
NIAID E-096-2019-0-PCT-02 HUMAN IMMUNODEFICIENCY VIRUS-SPECIFIC T CELL RECEPTORS PCT PCT PCT/US2020/013698 Expired
NCI E-248-2016-0-US-05 Plasma Autoantibody Biomarkers For Diagnosis Of Basal-like Breast Cancer US CON 16/743,906 Pending
NCI E-028-2019-0-CN-04 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-1 AND METHODS OF USE CN National Stage 202080010178.8 Pending
NCI E-028-2019-0-EP-05 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-1 AND METHODS OF USE EP National Stage 20704743.2 Pending
NCI E-028-2019-0-CA-03 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-1 AND METHODS OF USE CA National Stage 3125033 Pending
NCI E-028-2019-0-AU-07 HIGH AFFINITY MONOCLONAL ANTIBODIES TARGETING GLYPICAN-1 AND METHODS OF USE AU National Stage 2020212534 Pending
NIAID E-060-2015-0-AU-16 Novel Multivalent Nanoparticle-Based Vaccines AU DIV 2020200303 Pending
NCI E-172-2017-1-DE-01 METHOD FOR DETERMINING LYMPHOMA TYPE DE EP 18733500.5 Issued
NCI E-172-2017-1-FR-01 METHOD FOR DETERMINING LYMPHOMA TYPE FR EP 18733500.5 Issued
NCI E-172-2017-1-EP-02 METHOD FOR DETERMINING LYMPHOMA TYPE EP National Stage 18733500.5 Issued
NCI E-172-2017-1-GB-01 METHOD FOR DETERMINING LYMPHOMA TYPE GB EP 18733500.5 Issued
NCI E-265-2015-0-US-16 T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS US CON 16/739,310 11667692 Issued PDF
NCI E-050-2014-0-JP-17 Cancer Immunotherapy by Delivering Class II MHC Antigens Using a VLP-Replicon JP DIV 2020-001954 Pending
NCI E-140-2017-0-JP-06 COMPOUNDS FOR TREATING CANCER JP National Stage 2020-500657 Issued
NCI E-140-2017-0-US-07 ENGLERIN DERIVATIVES FOR TREATMENT OF CANCER US National Stage 16/628,768 11098054 Issued PDF
NCI E-028-2015-1-FR-01 Anti-Mutated Kras T Cell Receptors FR EP 20150279.6 Issued
NCI E-028-2015-1-DE-01 Anti-Mutated Kras T Cell Receptors DE EP 20150279.6 Issued
NCI E-028-2015-1-BE-01 Anti-Mutated Kras T Cell Receptors BE EP 20150279.6 Issued
NCI E-028-2015-1-AT-01 Anti-Mutated Kras T Cell Receptors AT EP 20150279.6 Issued
NCI E-028-2015-1-SE-01 Anti-Mutated Kras T Cell Receptors SE EP 20150279.6 Issued
NCI E-028-2015-1-ES-01 Anti-Mutated Kras T Cell Receptors ES EP 20150279.6 Issued
NCI E-028-2015-1-NL-01 Anti-Mutated Kras T Cell Receptors NL EP 20150279.6 Issued
NCI E-028-2015-1-TR-01 Anti-Mutated Kras T Cell Receptors TR EP 20150279.6 Issued
NCI E-028-2015-1-CH-01 Anti-Mutated Kras T Cell Receptors CH EP 20150279.6 Issued
NCI E-028-2015-1-GB-01 Anti-Mutated Kras T Cell Receptors GB EP 20150279.6 Issued
NCI E-028-2015-1-EP-15 Anti-Mutated Kras T Cell Receptors EP DIV 20150279.6 Issued
NCI E-028-2015-1-IT-01 Anti-Mutated Kras T Cell Receptors IT EP 20150279.6 Issued
NCI E-028-2015-1-IE-01 Anti-Mutated Kras T Cell Receptors IE EP 20150279.6 Issued
NCI E-028-2015-1-HU-01 Anti-Mutated Kras T Cell Receptors HU EP 20150279.6 Issued
NCI E-140-2017-0-DE-08 COMPOUNDS FOR TREATING CANCER DE EP 18745789.0 Issued
NCI E-140-2017-0-FR-10 COMPOUNDS FOR TREATING CANCER FR EP 18745789.0 Issued
NCI E-140-2017-0-EP-05 COMPOUNDS FOR TREATING CANCER EP National Stage 18745789.0 Issued
NCI E-140-2017-0-ES-09 COMPOUNDS FOR TREATING CANCER ES EP 18745789.0 Issued
NCI E-140-2017-0-GB-11 COMPOUNDS FOR TREATING CANCER GB EP 18745789.0 Issued
NIAID E-001-2017-1-US-03 ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTION US National Stage 16/608,386 11236151 Issued PDF
NCI E-140-2017-0-CA-04 COMPOUNDS FOR TREATING CANCER CA National Stage 3068980 Pending
NCI E-050-2014-0-EP-16 CANCER IMMUNOTHERAPY BY DELIVERING CLASS II MHC ANTIGENS AND A COSTIMULATORY SIGNAL PROTEIN USING A VLP-REPLICON EP DIV 20150087.3 Issued
NCI E-040-2019-0-PCT-02 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors PCT PCT PCT/US2020/012021 Expired
NCI E-040-2019-0-CN-05 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors CN National Stage 202080008456.6 Pending
NCI E-040-2019-0-EP-06 Cross Species Single Domain Antibodies Targeting Mesothelin For Treating Solid Tumors EP National Stage 20703568.4 Pending